Indivumed Therapeutics is a global oncology company, with a focus on bioinformatics and multi-omics-based oncology R&D. By unraveling the complex mechanisms of cancer, we shape a path toward precision oncology.

Through a global network of selected partner clinics, we maintain a unique database of proprietary multi-omics and clinical datasets that reflect the molecular reality of cancer at an unparalleled level.

By mapping the molecular reality of solid cancer and illuminating biological correlates we develop a true picture of oncological diseases. This allows us to collaborate with pharmaceutical companies to initiate new R&D programs and contribute our expertise, skills and knowledge throughout the drug development process.


Change is part of our history. For over 20 years, Indivumed has continued to evolve, forging valuable relationships around the world, and earning an outstanding reputation in the scientific community. We are always looking for new partnerships and methods to support the realization of our vision.

Explore the highlights of our journey:

2023 - A new, exciting future 

Indivumed evolves into Indivumed Therapeutics after the acquisition of Indivumed Services GmbH and its CRO service offerings by Crown Bioscience. Leveraging its global clinical cooperation with leading cancer clinics in Europe, Americas, and Asia and its unique multi-omics database Indivumed Therapeutics will drive data driven drug and diagnostic development.

Read more

2022 - On our Mission

We remain firmly focused on our mission: to support precision oncology. In January, the IndivuType project receives 4.3 million euros in EU funding from the ERDF structural fund. It’s another important boost for us to continue pursuing our goal beyond mere profit maximization.

2021 - Unraveling

Our groundbreaking data analytics platform sees the light of day: nRavel®. Utilizing cutting-edge AI technology and the world’s most comprehensive multi-omics cancer database, the platform helps to literally unravel the complexity of cancer.

2018 - We Have a Type

Supported by the European Fund for Strategic Investments (EFSI), the European Investment Bank (EIB) provides us with a EUR 40 million loan. Thanks to this and additional private funding, just one year later we are able to launch IndivuType, the world’s first real multi-omics knowledge and discovery solution.

2017 - Networking

Our clinical network reaches an important milestone: as the first partner in Asia, the Indian Institute of Technology in Madras joins our ever-growing global network, closely followed in 2018 by A*STAR’s Institute of Molecular and Cell Biology (IMCB) in Singapore. To date, the network consists of more than 100 permanent clinical partners, including leading hospitals, clinics, and oncology practices in Europe, North America, and Asia.

2008 - Drawing Blood

Together with scientists led by Professor Bert Vogelstein from Johns Hopkins University, we found Inostics GmbH to elaborate a new system of cancer gene diagnostics from blood. A few years later, the team is recognized by the AACR for its pioneering work in using cancer mutations as biomarkers in the context of liquid biopsies – a dramatic technological advancement in detecting cancer that defined a new field in oncology. Inostics is sold in 2013 to allow Indivumed to pursue other areas of research.

2005 - The Visionary

The jury of Deutscher Gründerpreis (German Founders Award) honors Hartmut Juhl with the award in the “Visionary” category. The prestigious award celebrates outstanding entrepreneurial achievements and recognizes personalities who turn visions into ventures.

2004 - New World

We expand overseas, and in April 2004 found Indivumed Inc. The American subsidiary is initially limited to sales and the development of the US clinical network. Today, the company has long had its own laboratory operations for customers in the United States.

2002 - Indi… what?

As early as September 2001, Dr. Hartmut Juhl starts Indivumed GmbH. Shortly afterwards, Dr. Carsten Zornig, Dr. Peter Layer, and Frank Oertel join as cofounders. Despite – or perhaps because of – the name, which might be difficult to pronounce at first, investors are quickly found. With them and the first five employees, operations begin April 5, 2002. Soon after, Indivumed is awarded the Hamburger Gründerpreis for being the best start-up company in Hamburg.


“At Indivumed we are united by a shared responsibility: using our unique expertise and skill sets to work toward individualized cancer diagnosis and treatment for every patient.”

Prof. Dr. med. Hartmut Juhl, Founder and CEO

Prof. Dr. med. Hartmut Juhl
Founder and Chief Executive Officer

Nils Schumacher
Chief Operating Officer

Dr. Jobst Landgrebe
Chief Technology Strategist

Dr. Stephan Schüller 
Chief Financial Officer

Gudrun Niewel
Senior Vice President Finance

Martin Heuseler
Vice President Finance

Dr. Jonathan Woodsmith  
Vice President Advanced Analytics & AI

Nina Gabelia, MD, MPH
Vice President Global Clinical Network Operations

Rene Steen
Vice President Information Technology

Dr. Hans Vanhooren
Vice President Business Development

Kristin Maack
Vice President Marketing & Corporate Communications

Dr. Daniel Pohlmann
Senior Director Oncology Analytics


If you are interested in a collaborative partnership or see Indivumed as your next employer, please do not hesitate to get in touch. We look forward to hearing from you.